| # | Drug | Count |
|---|---|---|
| 0 | DEXAMETHASONE | 59 |
| 1 | DEXAMETHASONE 1.5 MG | 59 |
| 2 | CYCLOPHOSPHAMIDE | 58 |
| 3 | CYCLOPHOSPHAMIDE FOR INJECTION | 58 |
| 4 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 58 |
| 5 | GEMCITABINE HYDROCHLORIDE | 56 |
| 6 | DOXORUBICIN | 55 |
| 7 | GEMCITABINE | 51 |
| 8 | CISPLATIN | 49 |
| 9 | ETOPOSIDE | 48 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | ETOPOSIDE PHOSPHATE | 13 | 0.0080 |
| 1 | L-TRYPTOPHAN | 1 | 0.0023 |
| 2 | CEDAZURIDINE AND DECITABINE | 2 | 0.0020 |
| 3 | AXICABTAGENE CILOLEUCEL | 17 | 0.0017 |
| 4 | POLATUZUMAB VEDOTIN | 17 | 0.0017 |
| 5 | ATRACURIUM BESYLATE | 1 | 0.0014 |
| 6 | CLOFARABINE | 3 | 0.0013 |
| 7 | ARSENIC TRIOXIDE | 3 | 0.0013 |
| 8 | DINUTUXIMAB | 1 | 0.0012 |
| 9 | BENDAMUSTINE HCL | 17 | 0.0011 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 88 |
| 1 | Alkylating Drug [EPC] | 72 |
| 2 | Platinum-based Drug [EPC] | 63 |
| 3 | Topoisomerase Inhibitor [EPC] | 50 |
| 4 | Nucleoside Metabolic Inhibitor [EPC] | 47 |
| 5 | Thalidomide Analog [EPC] | 39 |
| 6 | Microtubule Inhibitor [EPC] | 38 |
| 7 | CD20-directed Cytolytic Antibody [EPC] | 35 |
| 8 | Kinase Inhibitor [EPC] | 29 |
| 9 | Proteasome Inhibitor [EPC] | 29 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | CD38-directed Cytolytic Antibody [EPC] | 14 | 0.0024 |
| 1 | CD19-directed Chimeric Antigen Receptor [EPC] | 17 | 0.0017 |
| 2 | Glycolipid Disialoganglioside-directed Antibody [EPC] | 1 | 0.0009 |
| 3 | Topoisomerase Inhibitor [EPC] | 50 | 0.0006 |
| 4 | BCL-2 Inhibitor [EPC] | 26 | 0.0004 |
| 5 | Alkylating Drug [EPC] | 72 | 0.0003 |
| 6 | Histone Deacetylase Inhibitor [EPC] | 1 | 0.0003 |
| 7 | Proteasome Inhibitor [EPC] | 29 | 0.0003 |
| 8 | Platinum-based Drug [EPC] | 63 | 0.0002 |
| 9 | Microtubule Inhibitor [EPC] | 38 | 0.0002 |